Daliresp (roflumilast) Drug Information: Description, User Reviews, Drug Side Effects, Interactions

Pill Identifier Search

May 26, 2012

Daliresp

Chronic Obstructive Pulmonary Disease »

What is COPD?

Chronic obstructive pulmonary disease (COPD) is comprised primarily of three related conditions - chronic bronchitis, chronic asthma, and emphysema. In each condition there is chronic obstruction of the flow of air through the airways and out of the lungs, and the obstruction generally is permanent and may be progressive over time.

While asthma features obstruction to the flow of air out of the lungs, usually, the obstruction is reversible. Between "attacks" of asthma the flow of air through the airways typically is normal. These patients do not have COPD. However, if asthma is left untreated, the chronic inflammation associated with this disease can cause the airway obstruction to become fixed. That is, between attacks, the asthmatic patient may then have abnormal air flow. This process is referred to as lung remodeling. These asthma patients with a fixed component of airway obstruction are also considered to have COPD.

Often patien...

Read the Chronic Obstructive Pulmonary Disease article »

« Previous
1
2
3
4
5
6
7
8
9
10
Next »

Daliresp User Reviews >>

Daliresp

Understanding COPD Slideshow Pictures

Bronchitis Pictures Slideshow

How Smoking Affects Your Looks & Life Slideshow

font size

DALIRESP®
(roflumilast)

DRUG DESCRIPTION

The active ingredient in DALIRESP tablets is roflumilast. Roflumilast and its active metabolite (roflumilast N-oxide) are selective phosphodiesterase 4 (PDE4) inhibitors. The chemical name of roflumilast is N-(3,5-dichloropyridin-4-yl)-3-cyclopropylmethoxy-4difluoromethoxy-benzamide. Its empirical formula is C₁₇H₁₄Cl₂F₂N₂O₃ and the molecular weight is 403.22.

The chemical structure is:

DALIRESP® (roflumilast) Structural Formula Illustration

The drug substance is a white to off-white non-hygroscopic powder with a melting point of 160°C water and hexane, sparingly soluble in ethanol and freely soluble in acetone.

DALIRESP is supplied as white to off-white, round tablets, embossed with “D” on one side and “500” on the other side. Each tablet contains 500 mcg of roflumilast.

Each tablet of DALIRESP for oral administration contains the following inactive ingredients: lactose monohydrate, corn starch, povidone and magnesium stearate.

What are the precautions when taking roflumilast (Daliresp)?

Before taking roflumilast, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.

Before using this medication, tell your doctor or pharmacist your medical history, especially of: liver disease, cancer, heart disease (such as heart failure), current/past infections (such as tuberculosis, herpes), mental/mood disorders (depression, thoughts of suicide), unexplained/extreme weight loss, immune system disorders (such as lupus, HIV).

This drug may make you dizzy. Do not drive, use machinery, or do any activity that requires alertness until you are sure you can perform such activities safely. Limit...

Read All Potential Precautions of Daliresp »

Last reviewed on RxList: 4/27/2012
This monograph has been modified to include the generic and brand name in many instances.